BREAST CANCER
familial predisposition has been appreciated by the presence of BRCA1 and BRCA2
but increasingly we find young women with breast cancers who do not carry the mutation expected.  By their age and family history, we know there must be a genetic predisposition for the particular cancer of the breast to occur.
1.Mutation in the genes regulating or acting in the vicinity of the BRCA.
For medicine to advance and allow better use of limited resources and decrease the burden of side effects for our patients, It would be critical that new sets of genes enter the standard detection/category testing in the management of Breast Cancer. There are over 100 Mutations knwon!

2As far as BRCA2 is concerned, interaction with RAD51 has been suggested.   Ween et al:"versican and hyaluronan (HA) which interacts with the HA receptor, CD44, have been shown to play critical roles in ovarian cancer metastasis."  These molecule states (isoforms) have been found to be increasingly affected by interaction with growth factors   TGF and even PDGF.  (early detection of metastatic disease).  They should enter biomarker testing.

3.BRCAs are "wild gene"  first because there are hundred of these Mutations
and also because Wikipidea describes multiple various interactions:

"BRCA1 has been shown to interact with

• ABL1,^[102]
• AKT1,^[103][104]
• AR,^[105]
• ATR,^{[106][107][108][109]}
• ATM,^{[10][106][107][108][109][110][111]}
• ATF1,^[112]
• AURKA,^[113]
• BACH1,^[114]
• BARD1,^{[23][31][35][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141][142]}
• BRCA2,^{[120][143][144][145]}
• BRCC3,^[120]
• BRE,^[120]
• BRIP1,^{[27][146][147][148][149][150]}
• C-jun,^[151]
• CHEK2,^[152][153]
• CLSPN,^[154]
• COBRA1,^[155]
• CREBBP,^{[140][156][157][158][159]}
• CSNK2B,^[160]
• CSTF2,^[125][126]
• CDK2,^{[29][161][162]}
• DHX9,^[163][164]
• ELK4,^[165]
• EP300,^[156][158]
• ESR1,^{[158][166][167][168]}
• FANCA,^[169]
• FANCD2,^[122][144]
• FHL2,^[170][171]
• H2AFX,^{[115][119][172]}
• JUNB,^[151]
• JunD,^[151]
• LMO4,^[173][174]
• MAP3K3,^[175]
• MED1,^[147]
• MED17,^{[130][147][176]}
• MED21,^[177]
• MED24,^[147]
• MRE11A,^{[10][130][178][179]}
• MSH2,^[10][31]
• MSH3,^[31][146]
• MSH6,^[10][31]
• Myc,^{[35][180][181][182]}
• NBN,^{[10][130][178]}
• NMI,^[180]
• NPM1,^[121]
• NCOA2,^[146][183]
• NUFIP1,^[184]
• P53,^{[120][157][185][186][187]}
• PALB2,^[188]
• POLR2A,^{[130][177][189][190]}
• PPP1CA,^[191]
• Rad50,^{[10][130][178]}
• RAD51,^{[31][120][143][192]}
• RBBP4,^[193]
• RBBP7,^{[193][194][195]}
• RBBP8,^{[136][146][196][197][198][199][200]}
• RELA,^[140]
• RB1,^{[193][201][202]}
• RBL1,^[201]
• RBL2,^[201]
• RPL31,^[195]
• SMARCA4^[203][204]
• SMARCB1,^[203]
• STAT1,^[205]
• UBE2D1,^{[115][116][117][118][119][120][121][122][123][124]}
• USF2,^[206]
• VCP,^[207]
• XIST,^[208][209]
• ZNF350,^[210]"""
•  
• ^{of interest to us at CBCM are interaction with "BARD1,E3,VCP, SWI/SNF,Cobra1,Mir-17, Mir-30,ATM,MRE 11, PARP, PALB2,RAD51"}